High-quality evidence guiding optimal transfusion and other supportive therapies to reduce
bleeding is needed to improve outcomes for patients with either severe bleeding or …

Pathogen inactivation or reduction technologies for platelet components have been
proposed to secure the microbial safety of this component, and particularly the microbial …

Background Immune thrombocytopenia (ITP) is an autoimmune disease characterized by
low platelet counts and increased risk of bleeding. In preparation for an upcoming guideline …

Background Patients with haematological malignancies often develop thrombocytopenia as
a consequence of either their disease or its treatment. Platelet transfusions are commonly …

Background Bleeding is common in patients with haematological malignancies undergoing
intensive therapy. We aimed to assess the effect of tranexamic acid on preventing bleeding …

Background Bleeding is a primary outcome for many transfusion‐related trials in acute
leukaemia (AL) patients, typically graded using the World Health Organisation (WHO) …

Background The short shelf‐life of liquid‐stored platelets (LP) at 20–24° C poses shortage
and wastage challenges. Cryopreserved platelets have significantly extended shelf‐life, and …

Introduction: Acute leukemia (AL) is a rapidly progressive disease. AL and induction
chemotherapy lead to an increased risk of bleeding. Bleeding is measured in clinical trials …

Cryopreserved and lyophilized platelets have a long, but limited, history of human use that
dates back to the 1950s yet involves a small number of total study subjects (Fig. 9.1) …

The transfusion of platelet concentrates from donor to recipient is a time-consuming process.
It was developed following the demonstration by Gaydos of the link between the extent of …